Holen Sie sich die Stockscreener-App
2.09
0.72%
0.015
Vorhandelsmarkt:
2.08
-0.010
-0.48%
Schlusskurs vom Vortag:
$2.075
Offen:
$2.07
24-Stunden-Volumen:
573.46K
Relative Volume:
0.37
Marktkapitalisierung:
$355.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.8246
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
-7.93%
1M Leistung:
-25.62%
6M Leistung:
+104.90%
1J Leistung:
-79.88%
1-Tages-Spanne:
$2.05
$2.155
1-Wochen-Bereich:
$2.05
$2.36
52-Wochen-Spanne:
$0.611
$11.57
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.09 | 352.62M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
MACD Signal: Can Neumora Therapeutics Inc stock beat market expectations this quarterJuly 2025 Update & Verified Chart Pattern Signals - BỘ NỘI VỤ
Can Neumora Therapeutics Inc. stock weather global recession2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
How Neumora Therapeutics Inc. stock reacts to job market dataQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
Is Neumora Therapeutics Inc. stock attractive for ETFsPortfolio Growth Summary & Technical Buy Zone Confirmation - Newser
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
What momentum indicators show for Neumora Therapeutics Inc. stockGold Moves & Safe Capital Investment Plans - Newser
Neumora Therapeutics (NMRA) Stock Analysis Report | Financials & Insights - Benzinga
Neumora Therapeutics stock rating upgraded by RBC Capital on NLRP3 potential - Investing.com Canada
Neumora Therapeutics Shares Rise After RBC Upgrade - marketscreener.com
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset (NMRA:NASDAQ) - Seeking Alpha
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline - Benzinga
This Chevron Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
RBC Capital Upgrades Neumora Therapeutics (NMRA) - Nasdaq
RBC Upgrades Neumora Therapeutics to Outperform From Sector Perform, Raises Price Target to $7 From $4, Keeps Speculative Risk - marketscreener.com
Can Neumora Therapeutics Inc. stock beat market expectations this quarterWeekly Market Report & Low Risk Profit Maximizing Plans - BỘ NỘI VỤ
What drives Neumora Therapeutics Inc stock priceIPO Market Watch & Outstanding Portfolio Tips - earlytimes.in
Neumora Therapeutics (NMRA) Price Target Increased by 21.43% to 8.67 - MSN
AlphaCore Capital LLC Invests $248,000 in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Neumora Therapeutics thanks stakeholders for supporting brain disease therapy mission - Traders Union
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Neumora Issues Shares Following Loan Conversion Notice - MSN
FINAL REMINDER NMRA DEADLINE: Bronstein, Gewirtz & Grossman LLC A - The National Law Review
How Neumora Therapeutics Inc. stock trades before earningsPortfolio Update Report & Weekly Setup with ROI Potential - newser.com
How Neumora Therapeutics Inc. stock reacts to oil pricesJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
Is Neumora Therapeutics Inc. stock oversold or undervalued2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
Chart overlay techniques for tracking Neumora Therapeutics Inc.Trade Entry Summary & Proven Capital Preservation Methods - newser.com
Neumora Therapeutics price target raised to $3 from $2 at Stifel - MSN
What momentum shifts mean for Neumora Therapeutics Inc.Quarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Can Neumora Therapeutics Inc. stock maintain growth trajectoryGlobal Markets & Accurate Trade Setup Notifications - newser.com
How to build a custom watchlist for Neumora Therapeutics Inc.Weekly Stock Summary & Daily Volume Surge Signals - newser.com
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsIndex Update & Risk Controlled Daily Trade Plans - newser.com
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com India
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $3.00 at Stifel Nicolaus - MarketBeat
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):